Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The trial objectives were to investigate the tolerability and pharmacokinetics of 80 mg telmisartan and 2, 4 or 6 mg lacidipine administered concurrently.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Lacidipine; Telmisartan

Criteria

Inclusion Criteria:

• Healthy male caucasian subjects as determined by results of screening

• Written informed consent in accordance with Good Clinical Practice and local legislation given

• Age >= 18 and <= 50 years

• Broca >= -20% and <= + 20%

Exclusion Criteria:

• Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG) deviating from normal and of clinical relevance

• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

• Surgery of gastrointestinal tract (except appendectomy)

• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders

• History of orthostatic hypotension, fainting spells or blackouts

• Chronic or relevant acute infections

• History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator

• Intake of drugs with a long half-life (> 24 hours) (<= 1 month prior to administration or during the trial)

• Use of any drugs which might influence the results of the trial (<= 10 days prior to administration or during the trial)

• Participation in another trial with an investigational drug (<= 2 months prior to administration or during the trial)

• Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)

• Inability to refrain from smoking on study days

• Alcohol abuse (> 60g/day)

• Drug abuse

• Blood donation > 100 ml (<= 4 weeks prior to administration or during the trial)

• Excessive physical activities (<= 10 days prior to administration or during the trial)

• Any laboratory value outside the reference range of clinical relevance